J

Johnson & Johnson

Makes prescription drugs and medical devices

Principal Laboratory Automation Scientist

Full-TimeUpdated Deadline 11/7/26
No salary listed
Expert
Bachelor's, Master's, PhD
Spring House, PA, USA
Hybrid
Biology & Biotech

About the job

Requirements
  • A minimum of a bachelor's degree in Life Science, Analytical Science, Engineering, Computer Science, Laboratory Automation, or a related field is required.
  • A bachelor's degree with 10 or more years, a master's degree with 8 or more years, or a PhD with 5 or more years of relevant laboratory automation, scientific automation, analytical automation, high-throughput discovery, or workcell integration experience is required.
  • Demonstrated understanding of laboratory workflows, sample handling, plate and tube formats, assay execution, consumable preparation, run documentation, and data capture is required.
  • Hands-on or practical experience with automated liquid handlers or integrated laboratory automation equipment appropriate to the level of the role is required.
  • Ability to translate scientific workflows into executable automated methods, worklists, run states, exception pathways, and user-facing procedures is required.
  • Working knowledge of sample identity, labware identity, reagent identity, consumable state, barcode traceability, metadata capture, and downstream data requirements is required.
  • Ability to collaborate with scientists, automation engineers, IT, data science, AI, EHS, facilities, vendors, and laboratory operations is required.
  • Recognized expertise in laboratory automation, integrated workcells, assay automation, workcell orchestration, scientific workflows, and data flow is required.
  • Ability to define architecture, standards, interface models, recovery logic, and data requirements across multidisciplinary teams is required.
Responsibilities
  • Define cross-workcell laboratory automation architecture spanning scientific requests, instruments, workcells, sample stores, consumable stores, scheduling layers, data systems, user interfaces, and model feedback loops.
  • Create standards for labware, sample identity, reagent identity, consumable identity, state models, method versioning, interface control, recovery logic, run context, data provenance, and operational handover.
  • Establish design patterns for request intake, automated worklist generation, queue management, workflow routing, workcell handoffs, exception handling, and data feedback into scientific decision making.
  • Define acceptance criteria for nominal workflows, edge cases, failure modes, recovery scenarios, operator interventions, data completeness, and lights-out readiness from a scientific workflow perspective.
  • Define scientific and technical requirements for integrated automation platforms supporting biologics discovery, small molecule discovery, protein engineering, screening, analytical sciences, NGS, cell-based assays, biophysics, protein characterization, and translational workflows.
  • Resolve complex issues spanning scientific method performance, liquid handling, assay suitability, automation constraints, orchestration, data flow, sample logistics, software behavior, facilities constraints, biosafety, and vendors.
  • Lead cross-functional investigations and improvement programs that increase reliability, scalability, data quality, throughput, scientific adoption, and model feedback utility.
  • Advise senior partners on workflow maturity, automation readiness, manual versus automated boundaries, standardization opportunities, and scientific risks before major investment decisions.
  • Lead throughput modeling, queue modeling, workflow simulation, digital twin strategy, AI-ready metadata, experimental provenance, sample lineage, failure annotations, and data contracts.
  • Shape roadmaps for autonomous execution, physical AI integration, closed-loop experimentation, human oversight, human intervention guardrails, and model feedback.
  • Define data quality expectations connecting instrument outputs, sample context, run metadata, environmental context, and scientific interpretation.
  • Mentor laboratory automation scientists and influence communities of practice around method robustness, data provenance, automated workflow design, and adoption.
  • Support technology evaluations, proof-of-concept studies, workflow readiness assessments, user demonstrations, and vendor evaluations for future automation capabilities.
  • Contribute to laboratory automation standards, workflow templates, data handoff expectations, training materials, and playbooks.
  • Support audit, inspection, or quality documentation requests where automated scientific workflows intersect with regulated or quality-driven environments.
  • Participate in lessons learned and continuous improvement activities to improve future automation delivery and adoption.
Desired Qualifications
  • An advanced degree is strongly preferred.
  • Experience with SDLs, digital twins, FAIR data, AI-ready metadata, SiLA 2, OPC UA, APIs, event-driven architectures, microservices, workflow engines, and Tier 1 integrator models is preferred.
  • Experience with biologics discovery, small molecule discovery, protein engineering, high-throughput screening, analytical sciences, NGS, cell-based assays, and model feedback workflows is preferred.
  • A record of scientific or technical innovation through platform deployments, invention disclosures, patents, publications, or external collaborations is preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
The Irish Times
Oct 28th, 2026
Johnson & Johnson buys Irish stroke care firm in multimillion euro deal

Sale of Neuravi is largest deal for a venture-backed medtech in Europe since 2009

Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.